ClinicalTrials.gg
RecruitingNCT04196595Updated Jul 3, 2024

Apple Women's Health Study

An observational study in Menstrual Cycle, Ovulation and Menstruation, sponsored by Apple Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-03.

Sponsored by Apple Inc. · Observational

How we know

From the registry’s dates

  • Started Nov 2019; still recruiting 7 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 183 studies in Polycystic Ovary Syndrome with a site in United States — 32 open to participants now, 42 under way, 1 of them phase 3. Polycystic Ovary Syndrome · United States.

Planned enrollment
Largest of 35
500,000 · median 65
Started
2019
with 8 others
Observational
37 of 183
8 open now
Primary completion
2029-11
later than 40 of 41 live
Registered
142nd of 183
by date

Among the 183 studies in Polycystic Ovary Syndrome with a site in United States, this one has the largest planned enrollment of the 35 observational ones that give a count, is one of 9 that started in 2019, is one of 37 observational ones, reaches primary completion later than 40 of the 41 other live ones, and was the 142nd registered.

Polycystic Ovary Syndrome

959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.

Browse Polycystic Ovary Syndrome studies →

Open to participants now

32 of the 183 studies in Polycystic Ovary Syndrome with a site in United States are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 183 studies in Polycystic Ovary Syndrome with a site in United States, or all of them as a file.
02

Study summary

This is an observational longitudinal study to advance the understanding of menstrual cycle and gynecologic health conditions including PCOS, infertility and breast cancer.The study will be hosted within the Research app(available on App Store), which allows a user to find, enroll, and participate in Apple-supported health-related research studies.

03

Conditions studied

  • Menstrual Cycle
  • Ovulation
  • Menstruation
  • Polycystic Ovary Syndrome
  • Infertility
  • Menopause
  • Reproduction
  • Reproductive Health

Keywords

  • Menstruation
  • Menstrual Cycle
  • Ovulation
  • Polycystic Ovary Syndrome
  • Infertility
  • Menopause
  • Reproduction
  • Reproductive Health
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Convenience sampling of individuals who have ever menstruated and meet other eligibility criteria

Eligibility criteria

Inclusion Criteria:

  • Have menstruated at least once
  • Be at least 18 years old (at least 19 years old in Alabama and Nebraska, at least 21 years old in Puerto Rico)
  • Live in the United States of America
  • Be comfortable communicating in written and spoken English
  • Have installed the Apple Research app on your iPhone
  • Not share your iCloud account or iPhone with anyone else
  • Be willing and able to provide to participate in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Identify Menstrual Cycle Patterns

    Characterized using duration of menstrual flow, and cycle length in unit of days.

    Time frame: Up to 10 years

  2. Epidemiologic Description of Menstrual Cycle

    Characterized using cycle patterns and self-reported demographics, no unit of measure

    Time frame: Up to 10 years

Secondary outcomes

  1. Determine prevalence of gynecologic health conditions

    Characterized using menstrual cycle patterns and self-reported health conditions, no unit of measure

    Time frame: Up to 10 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2019 (actual). Primary completion is estimated for Nov 2029, 120 months after the start.

Of 74 observational studies under Polycystic Ovary Syndrome, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 48. This study's planned 120 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2019
First posted
Dec 12, 2019
StartActual
Nov 14, 2019
Primary completionEst.
Nov 2029
CompletionEst.
Nov 2029
Last update
Jul 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04196595
Lead sponsor
Apple Inc.
Responsible party
Sponsor
First posted
Dec 12, 2019
Start date
Nov 14, 2019
Primary completion
Nov 2029 (estimated)
Completion
Nov 2029 (estimated)
Last update
Jul 3, 2024

Study contacts

Shruthi Mahalingaiah, MD
Contact
AppleWomensHealthStudy@hsph.harvard.edu
617-432-1356
Michelle A Williams, SM, ScD
principal investigator · Harvard School of Public Health (HSPH)
Russ B Hauser, MD, MPH, ScD
principal investigator · Harvard School of Public Health (HSPH)
Brent A Coull, PhD
principal investigator · Harvard School of Public Health (HSPH)
Shruthi Mahalingaiah, MD, MS
principal investigator · Harvard School of Public Health (HSPH)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion